Ocular Therapeutix Inc OCUL

OCUL stock selloff began on Monday after Kodiak Sciences and 4D Molecular posted updates from clinical trials of their eye-disease drugs.

Over the last six months, Ocular Therapeutix’s shares have sunk to $7.74, producing a disappointing 7.1% loss - a stark contrast to the S&P 500’s 16.6% gain. This might have investors contemplating their next move.

BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026. Upcoming Investor Conference: Chardan 10th Annual Healthcare Conference:Date: Tuesday, October 20, 2026Fireside Chat: 9:45 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Ne

OCUL’s selloff on Monday was spurred by clinical updates from competitors on their wet AMD treatments.

A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.

In the high-stakes realm of clinical-stage biotechnology, long-term shareholder value is fundamentally forged by pipeline assets that solve deep-seated clinical bottlenecks while offering significant pricing power and capital efficiency. Ocular Therapeutix (NASDAQ:OCUL) operates squarely at this intersection, pioneering bioresorbable hydrogel delivery systems designed to fundamentally alter how chronic retinal diseases are treated. The company’s core […]

BEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to nine newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listin

Healthcare stocks were falling pre-bell Tuesday, with the State Street Health Care Select Sector SPD

Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular’s plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission for wet AMD remains on track for 4Q 2026 NDA submission to include subjects that have received multiple AXPAXLI injections in support of the Company’s application for repeat dosing Commercial readiness accelerates ahead of potential 2027 launch as AXPAXLI is well positioned to pote

On August 3, Ocular Therapeutix (NASDAQ:OCUL) reported second-quarter 2026 financial results that read as much like a regulatory update as an earnings report. Management confirmed that AXPAXLI, its lead retinal disease candidate, remains on track for a new drug application submission for wet age-related macular degeneration in the fourth quarter of 2026, a plan the […]

BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September and October 2026. Upcoming Investor Conferences: Wells Fargo 21st Annual Healthcare Conference:Date: Thursday, September 10, 2026Ocular Therapeutix to host investor one-on-one meetingsLocation: Boston, MA Baird 2

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.

Ocular Therapeutix recently reported Q2 results that topped revenue and EPS expectations and shared that its pivotal phase 3 AXPAXLI trials remain on track for an FDA-aligned NDA submission targeted for Q4 2026. This combination of operational outperformance and regulatory clarity around AXPAXLI’s development path highlights how closely the company’s near-term outlook is tied to this single retinal asset. Next, we’ll examine how the strong quarterly performance and FDA-aligned AXPAXLI...

Ocular Therapeutix (OCUL) is back in focus after its Q2 report, where revenues and earnings per share surpassed analyst expectations, and management outlined progress on AXPAXLI phase 3 trials with an FDA aligned path toward an NDA in Q4 2026. See our latest analysis for Ocular Therapeutix. Ocular Therapeutix shares have been volatile, with the 30 day share price return of 29.06% and 90 day share price return of 34.63% coming after Q2 results and recent investor events, while the 1 year total...

Ocular Therapeutix now carries an updated fair value estimate of about US$27.09 per share, up from US$26.00, reflecting refreshed price target work in recent modeling. Recent Street commentary links these higher targets in the mid to high US$20s to views on Axpaxli’s market opportunity, competitive trial readouts, and the latest FDA interactions. As you read on, you will see how to track these shifting assumptions and what to watch as the Ocular Therapeutix story continues to evolve. Analyst...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Ocular Therapeutix (NASDAQ:OCUL) and its peers.

EyePoint Pharmaceuticals said on Monday that its late-stage trial of DURAVYU, an experimental long-lasting eye implant for wet age-related macular degeneration, missed its main goal.

EyePoint posted the results for its Phase 3 Lugano trial, which compared its Duravyu therapy with Aflibercept, the standard treatment for wet AMD.